Technology evaluation: FluMist, University of Michigan.
FluMist is an intranasal influenza vaccine, which has been developed by Aviron. The genetically engineered, live, attenuated, cold-adapted virus vaccine produces influenza infection without the symptoms. The product has been field for approval in the US, where Merrill Lynch expects it to be marketed by mid-2000 [336561].
Novartis Research Institute, Brunner Strasse 59, A-1235, Vienna, Austria. andreas.billich@pharma.novartis.com
A
A
Billich
D000281:Administration, Intranasal; D000328:Adult; D000818:Animals; D001709:Biotechnology; D002648:Child; D006801:Humans; D007252:Influenza Vaccines / Q000008:administration & dosage* / Q000009:adverse effects; D012449:Safety; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000009:adverse effects
D007252:Influenza Vaccines; D014614:Vaccines, Synthetic